Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

HHS said it would terminate Women’s Health Initiative, then reconsidered

On April 21, Women’s Health Initiative investigators were informed that HHS would be terminating the WHI Regional Center contracts at the end of the current fiscal year.

April 25, 2025

Vol.51 No.16

By Jacquelyn Cobb and Claire Marie Porter

In Brief

Swim Across America grants $900,000 toward gene editing innovation

Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies.

April 25, 2025

Vol.51 No.16

Clinical Roundup

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer

The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.

April 25, 2025

Vol.51 No.16

In Brief

Hope Rugo named director of City of Hope’s Women’s Cancers Program

Hope S. Rugo has joined City of Hope to lead its Women’s Cancers Program throughout the organization and breast medical oncology division section.

April 18, 2025

Vol.51 No.15

Clinical Roundup

Heated intraperitoneal chemotherapy associated with longer survival in ovarian cancer

Physicians at Tampa General Hospital and USF Health Morsani College of Medicine conducted a multicenter, retrospective cohort study and found that a highly specialized treatment—heated intraperitoneal chemotherapy delivered directly into the abdominal cavity, is associated with longer survival for women with metastatic epithelial ovarian cancer.

April 18, 2025

Vol.51 No.15

Clinical Roundup

Phase II trial analysis shows higher ORR in HR MDS when treated with bexmarilimab + azacitidine

Faron Pharmaceuticals Ltd. on April 14 announced positive topline results of the BEXMAB trial, which shows a high overall response rate among both frontline as well as relapsed/refractory high-risk myelodysplastic syndromes patients treated with a combination of bexmarilimab and azacitidine.

April 18, 2025

Vol.51 No.15

Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

YOU MAY BE INTERESTED IN

HHS said it would terminate Women’s Health Initiative, then reconsidered

Swim Across America grants $900,000 toward gene editing innovation

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer

Hope Rugo named director of City of Hope’s Women’s Cancers Program

Heated intraperitoneal chemotherapy associated with longer survival in ovarian cancer

Phase II trial analysis shows higher ORR in HR MDS when treated with bexmarilimab + azacitidine

Renew today!

Subscriber content

Never miss an issue!

Login